Sumitomo Pharma is a research-driven pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription drugs, with strategic emphasis on oncology, central nervous system (CNS)/psychiatry, and regenerative/cell medicine. The company operates primarily in Japan and the United States, its largest market, while maintaining a presence across North America, Europe, China, and Southeast Asia. Key competitive strengths include proprietary R&D capabilities, a pipeline of innovative modalities including small molecules and iPS cell-derived therapies (e.g., 'Amsheply,' Japan's first approved non-self iPS cell-derived dopaminergic neural progenitor cell product), and an integrated global operating platform.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Sumitomo Pharma is a research-driven pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription drugs, with strategic emphasis on oncology, central nervous system (CNS)/psychiatry, and regenerative/cell medicine. The company operates primarily in Japan and the United States, its largest market, while maintaining a presence across North America, Europe, China, and Southeast Asia. Key competitive strengths include proprietary R&D capabilities, a pipeline of innovative modalities including small molecules and iPS cell-derived therapies (e.g., 'Amsheply,' Japan's first approved non-self iPS cell-derived dopaminergic neural progenitor cell product), and an integrated global operating platform.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →